Lecithin/chitosan nanoparticle drug carrier improves anti-tumor efficacy of Monascus pigment rubropunctatin
Shilong Ning(Fuzhou University), Yunquan Zheng(Fuzhou University), C.Y. Wang(Fuzhou University), Jianmin Yang(Canadian Food Inspection Agency), Li Zhao(Fuzhou University), Xianai Shi(Fuzhou University)
Cited by 31
Related Papers
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
Fluidic Multivalent Membrane Nanointerface Enables Synergetic Enrichment of Circulating Tumor Cells with High Efficiency and Viability
|Journal of the American Chemical Society|2020|170
Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
|Journal of Pharmacology and Experimental Therapeutics|2008|107